Pesquisar
Centessa Pharmaceuticals PLC
CNTAAdicionar à lista de desejos
40.500USD
0.0000.00%
Horário de mercado （ET）Cotações atrasadas em 15 min
6.27BValor de mercado
PerdaP/L TTM
Mais detalhes de Centessa Pharmaceuticals PLC Empresa
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Informações de Centessa Pharmaceuticals PLC
Código da empresaCNTA
Nome da EmpresaCentessa Pharmaceuticals PLC
Data de listagemMay 28, 2021
CEOSaha (Saurabh)
Número de funcionários77
Tipo de títulosDepository Receipt
Fim do ano fiscalMay 28
Endereço3rd Floor
CidadeALTRINCHAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalWA14 2DT
Telefone447391789784
Sitehttps://www.centessa.com/
Código da empresaCNTA
Data de listagemMay 28, 2021
CEOSaha (Saurabh)
Executivos da empresa Centessa Pharmaceuticals PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
462.58K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
91.08K
+50.41%
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
3.89K
-1882.61%
Mr. Iqbal Hussain
Mr. Iqbal Hussain
General Counsel and Chief Compliance Officer, Company Secretary
General Counsel and Chief Compliance Officer, Company Secretary
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Francesco de Rubertis, Ph.D.
Dr. Francesco de Rubertis, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Brett I. W. Zbar, M.D.
Dr. Brett I. W. Zbar, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mary Lynne Hedley, Ph.D.
Dr. Mary Lynne Hedley, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Carol Stuckley
Ms. Carol Stuckley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
462.58K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
91.08K
+50.41%
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
3.89K
-1882.61%
Mr. Iqbal Hussain
Mr. Iqbal Hussain
General Counsel and Chief Compliance Officer, Company Secretary
General Counsel and Chief Compliance Officer, Company Secretary
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Francesco de Rubertis, Ph.D.
Dr. Francesco de Rubertis, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Centessa Pharmaceuticals PLC?
Os cinco principais acionistas de Centessa Pharmaceuticals PLC são: Dr. Arjun Goyal, M.D.
Quantas instituições possuem ações da Centessa Pharmaceuticals PLC (CNTA)?
Em 2026Q1, 276 instituições possuíam ações da Centessa Pharmaceuticals PLC, com valor de mercado aproximado de 150.25M, representando 97.10% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 12002120.00.
